The effect of two oral contraceptives containing 30 μ g ethinylestradiol+ 75 μ g gestodene
(EE GSD) or 30 μ g ethinylestradiol+ 150 μ g desogestrel (EE DG) upon serum lipids and …

The clinical and metabolic effects of a short-term treatment with a combination contraceptive
pill containing 30 mcg ethinylestradiol and 75 mcg gestodene were evaluated in a group of …

Introduction Estetrol (E4) is a native estrogen produced only by the fetal liver during
pregnancy. E4 is the first new estrogen to be used in hormonal contraception since the …

Objectives The primary objective of this analysis was to characterise the steady-state
pharmacokinetics (PK) of ethinylestradiol (EE) and drospirenone (DRSP) in a randomised …

Objectives: To evaluate tolerability and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3
mg oral contraceptive using pooled data from two, multicenter, phase 3 trials. Study design …

Introduction: A novel estrogen free contraceptive pill, with drospirenone 4 mg in a dosing
regimen of 24+ 4, has been developed with a pearl-index of 0.51 (95% CI 0.1054; 1.4922) …

Purpose: Steroid hormones in hormonal contraceptives influence a variety of metabolic
parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a …

Thrombotic risk is associated with the estrogen dose and type of progestin in combined oral
contraceptives. Studies published since 1990 showed that third-generation progestins have …

The efficacy and acceptability of two third generation oral contraceptives in Thai women
were evaluated in a prospective, open, group-comparative, randomized, multicenter trial of …

In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four
oral contraceptives (OCs) on lipid metabolism was investigated. Four groups composed of …